Trabectedin (Et-743): Evaluation of Its Use In Advanced Soft-Tissue Sarcoma

Patrick Schöffski(KU Leuven), Herlinde Dumez, Ivo De Wever, Cristiana Stefan(KU Leuven), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Paul M. Clément(Universitair Ziekenhuis Leuven), Raf Sciot(KU Leuven), Pascal Wolter(KU Leuven)

Future Oncology

July 30, 2007

10.2217/14796694.3.4.381

Cited by 29

Related Papers

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

|New England Journal of Medicine|2014|2.7k

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

|The Lancet|2012|2.1k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

|The Lancet Oncology|2014|1.2k

Lomustine and Bevacizumab in Progressive Glioblastoma

|New England Journal of Medicine|2017|994